Operational Costs Compared: SG&A Analysis of Alpine Immune Sciences, Inc. and Soleno Therapeutics, Inc.

Biotech SG&A: Alpine vs. Soleno's Decade of Growth

__timestampAlpine Immune Sciences, Inc.Soleno Therapeutics, Inc.
Wednesday, January 1, 201422877092917513
Thursday, January 1, 201568440007878291
Friday, January 1, 201685860008366794
Sunday, January 1, 201760790006610381
Monday, January 1, 201883620006556000
Tuesday, January 1, 201994670006930000
Wednesday, January 1, 2020108990008758000
Friday, January 1, 20211456000010806000
Saturday, January 1, 2022179680009844000
Sunday, January 1, 20232222200013481000
Loading chart...

Unleashing insights

A Decade of SG&A: Alpine Immune Sciences vs. Soleno Therapeutics

In the ever-evolving biotech landscape, operational efficiency is paramount. Over the past decade, Alpine Immune Sciences, Inc. and Soleno Therapeutics, Inc. have demonstrated distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alpine's SG&A expenses surged by nearly 872%, peaking at $22.2 million in 2023. In contrast, Soleno's expenses grew by approximately 362%, reaching $13.5 million in the same year.

Key Insights

  • 2014-2017: Both companies maintained modest SG&A growth, with Alpine's expenses increasing by 166% and Soleno's by 127%.
  • 2018-2023: Alpine's expenses accelerated, outpacing Soleno's by a significant margin, reflecting strategic investments in operational capabilities.

This analysis underscores the importance of strategic financial management in biotech, where operational costs can dictate competitive advantage.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025